Literature DB >> 35484419

Circumventing the roadblocks to targeting EGFR-driven cancers.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35484419     DOI： 10.1038/s43018-022-00377-y

Source DB:  PubMed          Journal:  Nat Cancer        ISSN： 2662-1347


× No keyword cloud information.
  3 in total

Review 1.  Overcoming therapy resistance in EGFR-mutant lung cancer.

Authors:  Pasi A Jänne; Tony Mok; Solange Peters; Antonio Passaro
Journal:  Nat Cancer       Date:  2021-04-15

2.  Resistance is futile with fourth-generation EGFR inhibitors.

Authors:  Michelangelo Marasco; Sandra Misale
Journal:  Nat Cancer       Date:  2022-04

3.  An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.

Authors:  Ciric To; Tyler S Beyett; Jaebong Jang; William W Feng; Magda Bahcall; Heidi M Haikala; Bo H Shin; David E Heppner; Jaimin K Rana; Brittaney A Leeper; Kara M Soroko; Michael J Poitras; Prafulla C Gokhale; Yoshihisa Kobayashi; Kamal Wahid; Kari J Kurppa; Thomas W Gero; Michael D Cameron; Atsuko Ogino; Mierzhati Mushajiang; Chunxiao Xu; Yanxi Zhang; David A Scott; Michael J Eck; Nathanael S Gray; Pasi A Jänne
Journal:  Nat Cancer       Date:  2022-04-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.